Janssen Research & Development, LLC has partnered with Myriad Genetics, Inc. to use its BRACAnalysis test in connection with Janssen’s Phase III trial of Yondelis (trabectedin) in advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers. Specific terms were not disclosed.   “We are delighted to be collaborating with Janssen and applying our more than 20 years of BRCA-testing experience to help advance clinical cancer research,” said Mark C. Capone, presi...